Tirzepatide 'fractionation' guides on TikTok: safe math or risky DIY dosing?

What did @aureavittasuplementos actually say?

Honestly, this is a difficult video to fact-check because the transcript captured is incoherent, with phrases like "I will never forgive" and "I am without aa" bearing no relationship to the caption content. What we can work with is the video's stated premise: that a fractionation table for tirzepatide at 15mg/0.5ml concentration helps users divide doses "with safety, respecting the original concentration of the vial."

The caption explicitly frames this as an educational tool for people starting or continuing tirzepatide treatment. The hashtags, including "lipoless" and "mounjarocommunity," signal an audience actively using GLP-1 medications, often sourced outside standard pharmacy channels. The core claim, even without a coherent spoken transcript, is that a dose-fractionation table is a safe and simple guide. That claim deserves serious scrutiny.

Does the science back this up?

Tirzepatide's pharmacology is well-characterized, and the math of dilution is not the problem. The problem is context. Fractionation tables assume precise reconstitution, sterile technique, and accurate measurement, none of which can be guaranteed outside a licensed compounding pharmacy.

The FDA approved tirzepatide (Mounjaro, Zepbound) in specific pre-filled doses with defined escalation protocols. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) established efficacy and safety for doses of 5mg, 10mg, and 15mg given weekly using pharmaceutical-grade auto-injectors. Compounded tirzepatide, by contrast, is not FDA-approved and lacks the same sterility, potency verification, and stability data. A 2023 FDA statement explicitly warned that compounded versions may differ in concentration and quality from the approved product. Presenting a fractionation table as a "safe" dosing guide sidesteps all of this.

What did they get wrong (or right)?

Let's be direct: the framing is the problem, not necessarily the arithmetic. If a licensed prescriber and pharmacist are involved, understanding how a vial breaks down into individual doses is legitimate patient education. But this video is on TikTok, tagged with weight-loss community hashtags, and directed at general viewers. That context matters enormously.

What they got wrong is presenting dose fractionation as straightforwardly safe without acknowledging the regulatory and safety framework it requires. There is no mention of prescription requirements, no mention of sterile preparation, and no acknowledgment that compounded tirzepatide is not equivalent to brand-name Mounjaro or Zepbound. Research by Shank et al. (2023, Journal of the American Pharmacists Association) documented significant potency variability in compounded semaglutide samples, and there is reason to expect similar issues with compounded tirzepatide.

What they might have gotten right, in a narrow sense, is that the concentration math itself (15mg per 0.5ml equals 30mg/ml) is straightforward. That arithmetic is not wrong. But arithmetic is not a substitute for clinical oversight.

What should you actually know?

If you are using tirzepatide, compounded or otherwise, there are several things no TikTok fractionation table will tell you. First, dose escalation for tirzepatide is not just about volume. It is about managing gastrointestinal side effects and cardiovascular response over time. The approved escalation schedule exists because the SURMOUNT trials showed that slower titration reduces discontinuation due to side effects.

Second, drawing medication from a multi-use vial introduces contamination risk that single-dose auto-injectors are specifically designed to eliminate. Third, a fractionation table gives you no information about whether your compounded vial actually contains what the label says. Independent testing of compounded GLP-1 products has found inconsistencies. The FDA issued multiple safety alerts in 2023 and 2024 about compounded semaglutide dosing errors, some resulting in hospitalizations, and the same risk logic applies to tirzepatide.

Working with a licensed telehealth provider or endocrinologist who can monitor your response, adjust dosing based on clinical indicators, and prescribe through a verified pharmacy is not a bureaucratic inconvenience. It is the actual safety mechanism that a fractionation table cannot replace.

The bottom line

The video's premise treats a regulatory and clinical process as a math problem. It is not. Tirzepatide is a powerful dual GIP/GLP-1 receptor agonist with meaningful cardiovascular, gastrointestinal, and metabolic effects. Dosing it based on a social media table, without a prescriber and a verified compounding pharmacy in the loop, is a real risk. If you are seeing content like this, ask your provider before acting on it.